Načítá se...
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The struct...
Uloženo v:
| Vydáno v: | Pharm Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4596897/ https://ncbi.nlm.nih.gov/pubmed/25446773 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-014-1584-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|